Not sure why you believe Zami is doing this alone. Is he running the entire company and the production facility alone too?
Wish he'd said something about 3d process. Overall, was good to hear about the revolutionary aspect of stem cells as regenerative therapy.....how there are conditions for which medicine has no effect and only stem cells hold out hope and "opportunity."
My guess is they were quite impressed with the prospects; they just weren't compelled because no catalysts for near term. Science blows you away but the facts on the ground bring you back to earth.
As I said, "to get the ball rolling and begin to garner credibility for the company." Company needs to make another deal or two to boost credibility and visibility, show some revenue to stimulate more deals for the future. Nothing ventured; nothing gained.
Just want to add that this was my husband's argument to Anat about 3 years ago. She was clearly against this and, at the time, we hadn't much concern because we truly believed there would be more deals by now. As much as I love this company, I will use any pop above $9 to reduce my exposure and put it toward other positions which have short-term catalysts going for them unless, of course, something dazzling happens.
bauersteven....I have been willing to wait and have been waiting but "whatever the time frame turns out to be" is too vague even for me and I've been in and out a few times since 2009---but mostly in. I think it should be a mixed bag....some patient in-house development for the long-term MIXED with some early stage deals that are not as lucrative but get the ball rolling and begin to garner credibility for the company and its tech as the science is validated sooner, as I am sure much of it will be. Why can't we get a patchwork so short-term and long-term are in play?
For the dingbats here who say there are no "compelling data points" and who speak out of their #$%$....let's bump this up again.
It's worth what it's worth at any given time. Potentially, could be worth $60 or perhaps more. Until then, a few deals need to be made to prove the science to big pharma and the wider investment community. These molecules may be precious but their value has to be seen in context, imo.
What I believe happens repeatedly is that CGEN can't get deals or big, big investors because they block access to deals by asking too much. Until there are more Bayers and/or a treatment created in-house or not
that is proven efficacious, there will be no big deals and no milestone payments. Reduce the risk to potential deal-makers by asking less up front and let success speak for itself. This wait is interminable. Big money wants to see a track record that is not there.
"If I WERE running this company......" When using the conditional, the past tense is always "were, " not "was." Also, I agree with both subsequent posts which say, essentially, that it's about the process, not about some childish impatience inferring incompetence.
Wasn't YMAX, as a carrier, able to get numbers so that this development does not impact MJ to the extent it does Vonage? Not to be misunderstood, I would be glad that it has a positive impact for MJ. I just presumed it would not because they already had that edge.